Hydrophilic self-immolative linkers and conjugates thereof
The present disclosure provides compounds with a hydrophilic self-immolative linker, which is cleavable under appropriate conditions and incorporates a hydrophilic group to provide better solubility of the compound. The compounds of the present disclosure comprise a drug moiety, a targeting moiety capable of targeting a selected cell population, and a linker which contains an acyl unit, an optional spacer unit for providing distance between the drug moiety and the targeting moiety, a peptide linker which can be cleavable under appropriate conditions, a hydrophilic self-immolative linker, and an optional second self-immolative spacer or cyclization self-elimination linker.
1. A compound of the formula (I):
or a salt or solvate or stereoisomer thereof;
wherein:
T is a targeting moiety selected from the group consisting of: (a) an antibody comprising a heavy chain variable region comprising three CDRs from SEQ ID NO: 1 and a light chain variable region comprising three CDRs from SEQ ID NO: 2; and (b) an antibody comprising a heavy chain variable region comprising three CDRs from SEQ ID NO: 3 and a light chain variable region comprising three CDRs from SEQ ID NO: 4; and
-A-L 4 -L 3 -L 2 -X-L 1 -D is selected from the group consisting of:
2. The compound of claim 1 , wherein T is an antibody comprising a heavy chain variable region comprising amino acids 1-118 of SEQ ID NO: 1 and/or a light chain variable region comprising amino acids 1-113 of SEQ ID NO: 2.
3. The compound of claim 1 , wherein T is an antibody comprising a heavy chain variable region comprising amino acids 1-119 of SEQ ID NO: 3 and/or a light chain variable region comprising amino acids 1-108 of SEQ ID NO: 4.
4. A pharmaceutical composition comprising a compound of claim 1 , or a salt or solvate or stereoisomer thereof; and a pharmaceutically acceptable carrier.
5. A method of killing a cell, comprising administering to the cell an amount of the compound of claim 1 , or a salt or solvate or stereoisomer thereof, sufficient to kill the cell.
6. The method of claim 5 , wherein the cell is a cancer cell selected from a gastric cancer cell, pancreatic cancer cell, colorectal cancer cell, lung cancer cell, esophageal cancer cell, gallbladder cancer cell, head and neck cancer cell, liver cancer cell, endometrial carcinoma cell, salivary gland carcinoma cell, lymphoma cell, breast cancer cell, cervical cancer cell and ovarian cancer cell.
7. A method of treating cancer in an individual in need thereof comprising administering to the individual an effective amount of a compound of claim 1 , or a salt or solvate or stereoisomer thereof.
8. The method of claim 7 , wherein the cancer is gastric cancer, pancreatic cancer, colorectal cancer, lung cancer, esophageal cancer, gallbladder cancer, head and neck cancer, liver cancer, endometrial carcinoma, salivary gland carcinoma, lymphoma, breast cancer, cervical cancer or ovarian cancer.
9. A kit comprising a compound of claim 1 , or a salt or solvate or stereoisomer thereof.
10. The kit of claim 9 , further comprising instructions for use in the treatment of cancer.
11. A compound of the formula (IV):
or a salt or solvate or stereoisomer thereof; wherein T is an antibody comprising a heavy chain amino acid sequence of SEQ ID NO:1 and a light chain amino acid sequence of SEQ ID NO:2.
12. The compound of claim 1 , or a salt or solvate or stereoisomer thereof, wherein the compound is of the formula (IV):
wherein T is an antibody comprising a heavy chain amino acid sequence of SEQ ID NO:3 and a light chain amino acid sequence of SEQ ID NO:4.
13. The compound of claim 1 , or a salt or solvate or stereoisomer thereof, wherein the compound is of the formula (III):
wherein T is an antibody comprising a heavy chain amino acid sequence of SEQ ID NO:1 and a light chain amino acid sequence of SEQ ID NO:2.
14. The compound of claim 1 , or a salt or solvate or stereoisomer thereof, wherein the compound is of the formula (III):
wherein T is an antibody comprising a heavy chain amino acid sequence of SEQ ID NO:3 and a light chain amino acid sequence of SEQ ID NO:4.
15. The compound of claim 1 , or a salt or solvate or stereoisomer thereof, wherein the compound is of the formula (V):
wherein T is an antibody comprising a heavy chain amino acid sequence of SEQ ID NO:1 and a light chain amino acid sequence of SEQ ID NO:2.
16. The compound of claim 1 , or a salt or solvate or stereoisomer thereof, wherein the compound is of the formula (V):
wherein T is an antibody comprising a heavy chain amino acid sequence of SEQ ID NO:3 and a light chain amino acid sequence of SEQ ID NO:4.
17. A pharmaceutical composition comprising the compound of claim 11 , or a salt or solvate or stereoisomer thereof; and a pharmaceutically acceptable carrier.
18. A method of killing a cell, comprising administering to the cell an amount of the compound of claim 11 , or a salt or solvate or stereoisomer thereof, sufficient to kill the cell.
19. A method of treating cancer in an individual in need thereof comprising administering to the individual an effective amount of the compound of claim 11 , or a salt or solvate or stereoisomer thereof.
20. A kit comprising the compound of claim 11 , or a salt or solvate or stereoisomer thereof.